ARTICLE |
Correspondence to: Julian R. Thorpe, Electron Microscope and FACS Lab, School of Biological Sciences, University of Sussex, Falmer, Brighton BN1 9QG, East Sussex, UK.
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Parvulins are a distinct family within the peptidyl-prolyl cis-trans isomerase group of proteins that catalyse the cis-trans isomerization of proline-containing peptides. The intracellular distribution of a novel human parvulin homologue (hEPVH) has been investigated in a human kidney cell line (HEK 293) by immunogold labeling transmission electron microscopy (TEM). This showed hEPVH to be distributed throughout HEK 293 cells but in highest concentration within mitochondria. Unexpectedly, preabsorption of anti-hEPVH antiserum with recombinant hEPVH exaggerated the observed immunolabel density in a pattern that mirrored that of the endogenous hEPVH. The hEPVH protein itself was then used to label sections, and the specificity of its binding was confirmed with the use of polyclonal and monoclonal antibodies in conjunction with homologous and irrelevant protein controls. The pattern of hEPVH binding also mirrored that of endogenous hEPVH. A known chaperone protein, Pin1, was also found to bind to cells in a pattern mirroring that of the endogenous protein. This lends considerable weight to our hypothesis that hEPVH is binding to its target protein(s) within the cell, reflecting its postulated chaperone function. Finally, we suggest that chaperone proteins in general might be used as TEM probes for their target (or substrate) proteins. (J Histochem Cytochem 47:16331640, 1999)
Key Words: human eukaryotic parvulin homologue, Pin1, immunogold labeling, chaperone protein
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The peptidyl-prolyl cis-trans isomerase (PPIase) group of proteins comprises three structurally distinct families, cyclophilins, FKBPs and parvulins, which share a common ability to catalyze the cis-trans isomerization of proline-containing peptides (
The first member of the parvulin family of proteins was identified in E. coli (
A new subfamily of parvulin homologues has been identified (
In this study we investigated the subcellular localization of the hEPVH protein by immunogold labeling transmission electron microscopy (TEM). During the course of this work, a standard homologous preabsorption control for antiserum specificity was found to exaggerate, rather than abolish, the observed immunolabel density. We postulated that this putative chaperone protein might be binding to its target protein on the section surface, and a series of experiments was carried out to test this hypothesis.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell Line
HEK 293 cells were grown to confluency in DMEM supplemented with Glutamax (Life Technologies; Rockville, MD), 10% fetal calf serum (Life Technologies), 100 U/ml penicillin, and 0.1 mg/ml streptomycin (Sigma; Poole, UK).
Recombinant hEPVH and Pin1 Protein Production
PCR primers were designed to amplify the full-length hEPVH coding sequence (Genbank Accession No. AF143096) from human lung cDNA (Clontech; Basingstoke, UK). The product was cloned into pET21a (Novagen; Madison, WI) with the coding sequence in-frame with the vector's N-terminal T7-tag. A pET20b (Novagen) construct for un-tagged full-length Pin1 expression was kindly provided by Pfizer Central Research (Sandwich, UK). Transformed E. coli strain BL21 (DE3) cells (Novagen), were grown in 2YT broth to an OD600 of 0.8, and expression was induced with 1 mM IPTG. Cells were harvested 2 hr after induction and lysed in 50 mM Tris-HCl, 5 mM MgCl2, 2 mM CaCl2, 5% glycerol, 5 mM DTT (Sigma), pH 7.5 (for Pin1) or pH 8.9 (for hEPVH). Recombinant protein was purified to homogeneity (
Mass Spectrometry
Rec-hEPVH (0.5 mg/ml; c.30 µM) was analyzed in a Micromass TofSpec-E MALDI-TOF mass spectrometer. The sample spectrum was acquired in linear positive-ion mode using a matrix of 12 mg/ml sinapinic acid and was externally calibrated against cytochrome c and trypsinogen.
Preparation of Cells for Electron Microscopy
All the following procedures were carried out at 4C. After fixation for 3 hr in 4% formaldehyde plus 0.1% (vacuum-distilled) glutaraldehyde in PBS, 0.14 M, pH 7, the cells were rinsed thoroughly (five changes and left overnight) in PBS and dehydrated in an ethanol series (30%, 50%, 75%, 90% and 3 x 100%, 20 min each). The samples were then embedded in Unicryl resin (British BioCell International; Cardiff, UK) by a procedure slightly modified from
Antibodies and Gold Probes
Rabbit polyclonal antisera were raised to the purified recombinant hEPVH ([p]anti-hEPVH) by Cambridge Research Biochemicals (Northwich, Cheshire, UK). Western blot analysis of whole HEK 293 cell lysate has confirmed the specificity of this antiserum. Mouse anti-T7 Tag monoclonal antibody (hereon termed [m]anti-hEPVH) was obtained from Novagen. Goat anti-Pin1 polyclonal antisera to the C-terminus ([p]anti-(C)Pin1) and N-terminus ([p]anti-(N)Pin1) domains were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody to bovine growth hormone ([m]anti-bGH) was kindly donated by our colleague Prof. Mike Wallis (for specificity see
Immunogold Labeling TEM
For details of the precise immunolabeling methodology used throughout this work, please see
hEPVH Immunolabeling. Sections were blocked for 30 min in 1:10 normal goat serum at room temperature (RT) and then incubated overnight at 4C in 1:200 [p]anti-hEPVH. As a control, sections were concurrently incubated in preimmune rabbit serum (PIS) at similar dilution. After three 2-min rinses in PBS+, the sections were immunolabeled for 1 hr at RT in GaR5 and subsequently rinsed in PBS+ (three times for 10 min) and then distilled water (four times for 3 min). Sections were poststained in 0.5% aqueous uranyl acetate for 15 min.
Homologous and Heterologous Preabsorptions Liquid Phase. The [p]anti-hEPVH was preabsorbed (at the working dilution of 1:200) in 20 or 200 µg/ml recombinant hEPVH (rec-hEPVH) or 20 µg/ml Pin1 (rec-Pin1) for 48 hr at 4C. PIS and [p]anti-hEPVH (at similar dilution) minus this protein addition were set up concurrently for control immunolabelings.
Solid-phase Coupling of hEPVH to NHS-activated Sepharose. HiTrap NHS-activated affinity columns were obtained from Amersham Pharmacia Biotech. Rec-hEPVH was concentrated to 5 mg/ml using a centricon-3 column (Millipore; Watford, UK) and diluted in coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 8.3) to give a final concentration of 1 mg/ml. One ml of this solution was injected onto the activated column, which was then incubated at RT for 1 hr. Excess active groups were deactivated by serially washing the column with 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3, and 0.1 M acetate, 0.5 M NaCl, pH 4. A blank Sepharose column was made by loading coupling buffer only onto another column, incubating for 1 hr, and deactivating the excess groups in the same way as for the hEPVH column. Both columns were equilibrated in PBS+ before loading 1 ml of a 1:50 dilution of [p]anti-hEPVH and incubating at 4C for 1 hr. The preabsorbed antiserum was eluted from the column in 4 ml of PBS+ to obtain a 1:200 diluted antiserum which was used directly for immunolabeling.
Verification of Binding of Rec-hEPVH on the Preabsorbed Antibody to Sections. After homologously preabsorbed (with rec-hEPVH) [p]anti-hEPVH incubation and immunolabeling with GaR5, sections were incubated in a monoclonal antibody against the T7 tag of the rec-hEPVH ([m]anti-hEPVH; 50 µg/ml) and immunolabeled with GaM10. As a control for this latter immunolabeling, sections were incubated in an irrelevant monoclonal antibody ([m]anti-bGH; 87.5 µg/ml) before immunolabeling with GaM10.
Using Recombinant hEPVH and Pin1 to Label Cells. For rec-hEPVH labeling, this procedure was identical to the routine immunogold labeling except that an incubation in 20 µg/ml rec-hEPVH (in PBS+ for 24 hr at 4C, followed by either three or six 2-min PBS+ rinses) was inserted between the normal goat serum blocking and specific antibody ([p]anti-hEPVH or [m]anti-hEPVH) incubation steps. As controls, sections were concurrently incubated in PBS+ alone (in place of rec-hEPVH) and also (for the monoclonal antibody labeling) in an irrelevant protein [(bovine) growth hormone (bGH; 20 µg/ml)] which was immunolabeled with its specific monoclonal antibody ([m]anti-bGH; 87.5 µg/ml) and GaM10.
For rec-Pin1 labeling, sections were blocked in PBS+ for 30 min at RT, incubated in 20 µg/ml rec-Pin1 (as for rec-hEPVH), then immunolabeled with a mixture of 1:50 (4 µg/ml) [p]anti-(C)Pin1 and [p]anti-(N)Pin1 and subsequently pAG10. Other sections were concurrently incubated in PBS+ alone (in place of rec-Pin1) and either immunolabeled (as for the rec-Pin1 labeling) to reveal endogenous Pin1 protein or with normal goat serum (4 µg/ml).
Verification of the Specificity of Recombinant hEPVH Binding. To verify the specificity of rec-hEPVH binding, sections were preincubated in either the closely related protein rec-Pin1 or in the irrelevant protein bGH (both at 20 µg/ml for 24 hr at 4C) before rec-hEPVH incubation and immunolabeling as described above. As further controls, concurrent sections were preincubated in PBS+ alone (before rec-hEPVH incubation and immunolabeling) or in PBS+ followed by bGH incubation and immunolabeling with [m]anti-bGH (50 µg/ml). Finally, as a control for nonimmunological, hydrophobic protein interactions, sections were incubated in Pin1 and bGH (as above) and then immunolabeled with [p]anti-hEPVH.
Image Acquisition and Analysis
The immunolabeled thin sections were examined in a Hitachi-7100 TEM at 100 kV. Random images at x50,000 magnification were acquired digitally with an 800 x 1200 pixel charge-coupled device camera (Digital Pixel; Brighton, UK). The areas of the different cell compartments were computed (Kinetic Imaging; Liverpool, UK), gold particles counted, and the immunolabeling results expressed as numbers of gold particles per µm2. Means and standard errors (SEM) were calculated and t-tests were used for statistical analyses of significance.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Subcellular Distribution of Endogenous hEPVH Protein
Figure 1 shows the pooled results of three separate immunolabelings for endogenous hEPVH. These revealed the presence of hEPVH throughout the cells, but in higher concentration within the mitochondria. The immunolabeling of the latter organelles was confined to the matrix.
|
Preabsorption Results
Preabsorption of the [p]anti-hEPVH with its homologous antigen (rec-hEPVH at 20 µg/ml) greatly exaggerated, rather than abolished, the observed immunolabeling density (Figure 2). This increased immunolabeling density was some 11-, 14-, and 10-fold for the nuclear, cytoplasmic, and mitochondrial compartments, respectively. The pattern of distribution of this exaggerated immunolabeling was similar to that of the endogenous hEPVH protein. Preabsorption with an increased concentration of rec-hEPVH (200 µg/ml) also resulted in elevated immunolabel densities (not shown).
|
A (concurrent) heterologous preabsorption (with rec-Pin1 at 20 µg/ml) had only minor effects on immunolabeling density (Figure 2).
A homologous (rec-hEPVH-bound Sepharose) column preabsorption of the [p]anti-hEPVH resulted in an 88% reduction in immunolabel density over the mitochondria [compared with a blank column (n = 20); data not shown].
Verification of Binding of Recombinant hEPVH on the Preabsorbed Antibody to Sections
The results of immunolabeling sections initially with rec-hEPVH preabsorbed antiserum (and GaR5) and subsequently with [m]anti-hEPVH (and GaM10) confirmed the binding of the recombinant protein to the section. The cellular distribution of monoclonal immunolabeling (Figure 3) was similar to that of the preabsorbed polyclonal antiserum. A control incubation in an irrelevant monoclonal antibody ([m]anti-bGH) at a concentration higher (87.5 rather than 50 µg/ml) than the specific monoclonal exhibited extremely low levels of labeling.
|
Using Recombinant hEPVH to Label Cells
Incubation of sections in 20 µg/ml rec-hEPVH alone before immunolabeling with the [p]anti-hEPVH and GaR5 also resulted in increased immunolabeling. There was no difference in the immunolabeling density be-tween grids rinsed three or six times before transferring to the antibody (not shown). The immunolabeling pattern was similar to that of the rec-hEPVH-preabsorbed antibody (Figure 4). Two further immunolabelings carried out using a fresh batch of rec-hEPVH protein exhibited very high immunolabel densities (Figure 5A and Figure 5B). A separate incubation in 20 µg/ml rec-hEPVH followed by immunolabeling with the [m]anti-hEPVH and GaM10 confirmed the presence of the rec-hEPVH bound to the sections (Figure 5D, Figure 5E, and Figure 6).
|
|
|
As with the endogenous hEPVH, the immunolabeling of the mitochondria was confined to the matrix (Figure 5A and Figure 5E). It was also noted that there was some association of labeling with the cristae membranes (Figure 5B).
Verification of the Specificity of Recombinant hEPVH Binding
Preincubation with a closely related (Pin1) or an irrelevant (bGH) protein had no significant effect on rec-hEPVH binding (Figure 7). Only extremely low levels of nonspecific bGH binding were revealed by incubation in, and subsequent specific immunolabeling for, this protein. Incubation in the closely related (Pin1) or an irrelevant (bGH) protein before immunolabeling with [p]anti-hEPVH revealed label densities at endogenous levels. Therefore, nonimmunological, hydrophobic protein binding interactions were absent (not shown).
|
Mass Spectrometry of Rec-hEPVH
Mass spectrometry showed no evidence for rec-hEPVH dimers, there being a single peak in the sample spectrum equivalent to the molecular weight of the protein (not shown).
Subcellular Distribution of Endogenous Pin1 and Recombinant Pin1 Labeling of Cells
Immunolabeling for endogenous Pin1 revealed the presence of this protein throughout the cells but, in contrast to the distribution of the hEPVH protein, the highest label density was within the nuclear compartment (Figure 8, white columns). A control immunolabeling in nonimmune goat serum at an identical protein concentration exhibited extremely low levels of labeling.
|
Incubation of sections in 20 µg/ml rec-Pin1 alone before immunolabeling with the [p]anti-(C- and N-terminus) Pin1 and pAG10 resulted in increased immunolabeling densities over endogenous levels (Figure 8, black columns, and Figure 5C and Figure 5F). Similarly to the rec-hEPVH incubations, there was no difference in the immunolabeling density between grids rinsed three or six times before transferring to the antibody (not shown). As with the rec-hEPVH incubation results, the pattern of this increased labeling was similar to that of the endogenous protein.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The initial TEM immunogold labeling results for the distribution of endogenous hEPVH showed that it was present throughout the HEK 293 cells but in higher concentration within the mitochondria. A subsequent routine homologous (rec-hEPVH) preabsorption test for the polyclonal anti-hEPVH antiserum specificity yielded an unexpected result: the immunolabel density was greatly exaggerated rather than abolished. We therefore postulated that the rec-hEPVH (bound to the preabsorbed antibody) was binding to the section. In addition, because this increase in immunolabeling density appeared to mirror the distribution of the endogenous hEPVH, we suggest that the rec-hEPVH might be binding to its (unbound) target protein within the cell (the possibility of hEPVHhEPVH binding events was dismissed because mass spectrometry showed no evidence for rec-hEPVH dimerization).
We could not directly confirm the latter in the current absence of knowledge of this protein's identity and thus the lack of a specific antibody. However, immunolabeling of the sections incubated with homologously preabsorbed anti-hEPVH and subsequently with a monoclonal antibody against the (T7 tag of) rec-hEPVH lent convincing evidence: the pattern of this immunolabeling was similar to that of the preabsorbed antibody.
Concerns that the observed effect could be due to use of suboptimal concentrations of rec-hEPVH (despite calculations suggesting the opposite) during the initial (20 µg/ml hEPVH) preabsorption (causing signal amplification via, e.g., endogenous hEPVH-anti-hEPVH-rec-hEPVH-anti-hEPVH binding events) were allayed by the following. First, preabsorption with 200 µg/ml hEPVH also caused an increase in immunolabeling density. Second, incubation of sections in the rec-hEPVH protein alone [followed by thorough rinsing before subsequent immunolabeling with (non-preabsorbed) anti-hEPVH] exhibited a similar cellular binding pattern. The specific nature of this rec-hEPVH binding was confirmed by the results of incubations and preincubations with a related (rec-Pin1) and an irrelevant protein (bGH).
As a final test of our hypothesis, we investigated the subcellular distribution of the parvulin protein Pin1, a known chaperone protein with a known (predominantly nuclear, some cytoplasmic) localization (
These latter results therefore lend considerable weight to our argument that both hEPVH and Pin1 may be binding to their target proteins within the section, and support our theory that hEPVH, like Pin1, acts as a chaperone. It is noteworthy that the higher levels of rec-hEPVH binding in the mitochondria might reflect a higher level of unbound target protein. Therefore, this organelle might be a target for hEPVH protein activity.
In summary, this work reports on immunolabeling evidence of the differential binding of a putative (hEPVH) and a known (Pin1) chaperone protein to various cell compartments. Although enzymegold probes have been shown to bind to their substrates (
It should be noted that, as with standard immunogold labeling, the preparation of particular specimens/chaperone proteins must be optimized empirically. Undoubtedly, the preferred method will always involve minimizing the denaturation of proteins throughout the procedure. The use in this work of the acrylic resin Unicryl (after a minimal cold fixation) has apparently facilitated the maintenance of in vivo chaperone/target protein binding interactions. This recently developed resin minimizes protein denaturation, and its largely hydrophilic nature allows good access to aqueous solutions. These latter properties markedly improve the quality of immunolabeling (
![]() |
Acknowledgments |
---|
SLR is a recipient of a BBSRC CASE Award, sponsored by Pfizer Central Research (Sandwich, UK).
We would like to thank our colleagues Mike Wallis and John Armstrong for useful discussions concerning this research. We are also grateful to the former for the provision of bovine growth hormone and its specific monoclonal antibody. In addition, we would like to thank Colin Robinson, Richard Bazin, and Vikash Malde (Pfizer Central Research, UK) for provision of the Pin1 expression construct and for their assistance with hEPVH and Pin1 expression and purification. We also thank Chris Kowalczyk for carrying out the mass spectrometry. Finally, JRT would like to thank David Randall for looking after the day-to-day running of the lab during work on this project.
Received for publication April 23, 1999; accepted July 20, 1999.
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bendayan M (1981) Ultrastructural localization of nucleic acids by the use of enzyme-gold complexes. J Histochem Cytochem 29:531-541[Abstract]
Bogers JJ, Nibbeling HA, Deelder AM, Van Marck EA (1996) Quantitative and morphological aspects of Unicryl versus Lowicryl K4M embedding in immunoelectron microscopic studies. J Histochem Cytochem 44:43-48
Crenshaw DG, Yang J, Means AR, Kornbluth S (1998) The mitotic peptidyl-prolyl isomerase, Pin1, interacts with Cdc25 and Plx1. EMBO J 17:1315-1327
Fadool JM, Aggarwal SK (1990) Immunocytochemical demonstration of vasopressin binding in rat kidney. J Histochem Cytochem 38:7-12[Abstract]
Galat A (1993) Peptidylproline cistrans isomerases: immunophilins. Eur J Biochem 216:689-707[Abstract]
Hanes SD, Shank PR, Bostian KA (1989) Sequence and mutational analysis of ESS1, a gene essential for growth in Saccharomyces cerevisiae. Yeast 5:55-72[Medline]
Kay JE (1996) Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem J 314:361-385[Medline]
Lu KP, Hanes SD, Hunter A (1996) A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380:544-547[Medline]
Maleszka R, Hanes SD, Hackett RL, de Couet HG, Miklos GL (1996) The Drosophila melanogaster dodo (dod) gene, conserved in humans, is functionally interchangeable with the ESS1 cell division gene of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 93:447-451
Rahfeld JU, Schierhorn A, Mann K, Fischer G (1994b) A novel peptidyl-prolyl cis/trans isomerase from Escherichia coli. FEBS Lett 343:65-69[Medline]
Rahfeld JU, Rucknagel KP, Schelbert B, Ludwig B, Hacker J, Mann K, Fischer G (1994a) Confirmation of the existence of a third family among peptidyl-prolyl cis/trans isomerases. Amino acid sequence and recombinant production of parvulin. FEBS Lett 352:180-184[Medline]
Rudd KE, Sofia HJ, Koonin EV, Plunkett G, 3rd, Lazar S, Rouviere PE (1995) A new family of peptidyl-prolyl isomerases. Trends Biochem Sci 20:12-14[Medline]
Rulten SL, Thorpe JR, Kay JE (1999) Identification of eukaryotic parvulin homologues: a new subfamily of peptidyl-prolyl cis-trans isomerases. Biochem Biophys Res Commun 259:557-562[Medline]
Thorpe JR (1999) The application of LR Gold resin for immunogold labeling. In Hajibagheri MA, ed. Electron Microscopy Methods and Protocols. Methods in Molecular Biology Series. Vol 117. Totowa, NJ, Humana Press, 99-110
Thorpe JR, Ray KP, Wallis M (1990) Occurrence of rare somatomammotrophs in ovine anterior pituitary tissue studied by immunogold labeling and electron microscopy. J Endocrinol 124:67-73[Abstract]
Wasano K, Hirakawa Y (1997) Recombinant galectin-1 recognizes mucin and epithelial cell surface glycocalyces of gastrointestinal tract. J Histochem Cytochem 45:275-283
Wasano K, Hirakawa Y (1999) Two domains of rat galectin-4 bind to distinct structures of the intercellular borders of colorectal epithelia. J Histochem Cytochem 47:75-82